Analyst Insights - Digital Health Posts

Read our Analysts’ insights and expert opinions on the latest healthcare technology industry developments and market trends. Signify Research provides both free insights and premium insights which are only available to subscribers of "Signify Premium Insights".
Click on the premium insights link below to filter for just the premium content.

Signify Premium Insight: AI’s Personal Approach to Breast Imaging

Signify Premium Insights Subscription Required

February 7th 2023 – The breast imaging market was one of those most severely affected by the Covid-19 pandemic. This has led to some significant changes, but, as research manager Bhvita Jani and Senior Market Analyst Dr Sanjay Parekh explain, it has also facilitated the rise of new technologies and approaches.

Signify Premium Insight: Optum Health a Master of its own Destiny in Fully Accountable Care

Signify Premium Insights Subscription Required

7th February 2023 – Optum Health’s plans to usher more customers towards fully accountable care in 2023 will draw on its unique relationships. But how are providers navigating the shift to ‘two-sided risk’ alternative payment models?

Inpatient EHR Competitive Landscape and Market Trends within EMEA

The Inpatient EHR Market has undergone several changes recently, with the Covid-19 pandemic providing the conditions to catalyse development in many areas.

Signify Premium Insight: Perspectum’s Persuasive Value Proposition

Signify Premium Insights Subscription Required

February 2nd 2023 – Perspectum has recently secured $36m in Series C funding. It is a figure that, compared to its peers, is surprisingly low, particularly given Perspectum’s credentials. Is there a reason for this financial modesty?

Signify Premium Insight: MDR Postponement: Impact on EHR and Drug CDS Product Roadmap

Signify Premium Insights Subscription Required

2nd February 2023 – An EU Commission proposal to push back the deadline for re-certifying medical devices from May 2024 to May 2028 will dampen demand for more sophisticated drug Clinical Decision Support (CDS) products.